Market Overview:
The global injectable suspension budesonide market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of respiratory diseases, nose diseases, and inflammatory bowel diseases (IBD). Additionally, the growing awareness about the benefits of using budesonide for treating various medical conditions is also contributing to the growth of this market. Based on type, the global injectable suspension budesonide market can be segmented into 0.5mg and 1mg segments.
Product Definition:
Injectable Suspension Budesonide is a medication used to treat Crohn's disease, ulcerative colitis, and other conditions. It is a corticosteroid that reduces inflammation.
0.5mg:
Budesonide is a type of drug known as an anti-inflammatory agent. It works by reducing the production of cytokines, which are substances that cause inflammation. Inflammation is involved in many diseases and health problems such as asthma, COPD, arthritis and other autoimmune diseases like diabetes and thyroiditis.
1mg:
Budesonide is a type of drug known as an anti-inflammatory agent. It works by reducing the production of cytokines, which are substances that cause inflammation. Budesonide is used in the treatment of asthma and other chronic inflammatory diseases. The medicine comes in both 1 mg and 3 mg dosage forms with the brand name “Adcirca” being one such product available in India market for asthma patients.
The medicine has been approved by the U.
Application Insights:
The inflammatory bowel disease treatment segment dominated the global injectable suspension budesonide market in terms of revenue share in 2017. The high prevalence of Inflammatory Bowel Disease (IBD) such as Crohn¢â‚¬â„¢s disease and ulcerative colitis is anticipated to fuel the demand for budesonide tablets and injections during the forecast period. In addition, a growing number of product launches by various companies are expected to contribute towards market growth over the next eight years.
Budesonide nasal spray was estimated as one of the leading products used for rhinitis management across all age groups globally due to its anti-inflammatory & antiseptic properties. Its use is particularly prevalent among patients suffering from allergic rhinitis, chronic sinus infections, nasal polyps/canker sores and non-allergic rhinitis with no or minimal response to other treatments.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing awareness about immunotherapy drugs and favorable reimbursement policies. In addition, an increase in R&D activities by key companies is also anticipated to drive growth. For instance, Asthmaglobin Pharmaceuticals Inc., a U.S.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to rising healthcare expenditure by governments along with an increase in demand for cost-effective therapeutics that provide better patient outcomes at lower costs coupled with growing prevalence of respiratory diseases & disorders especially among children & adolescents are some factors driving growth in this region.
Growth Factors:
- Increasing prevalence of asthma and other respiratory diseases: The global Injectable Suspension Budesonide market is expected to grow at a CAGR of 5.5% during the forecast period, owing to the increasing prevalence of asthma and other respiratory diseases.
- Growing demand for generic drugs: The growing demand for generic drugs is another key growth driver for the global Injectable Suspension Budesonide market. Generic drugs are therapeutically equivalent to their branded counterparts but are available at a fraction of the cost. This is expected to drive the adoption of Injectable Suspension Budesonide in emerging markets in Asia Pacific and Latin America over the forecast period.
- Technological advancements in drug delivery systems: The development of novel drug delivery systems has led to an increase in uptake rates for injectable medications, thereby driving growth in the global Injectable Suspension Budesonide market. These systems offer improved patient compliance, safety, and efficacy as compared to traditional oral medications or injections administered using needles and syringes . Some such technologies include needle-free injection devices , microneedles , transdermal patches , etc., which are likely to boost adoption rates for injectables over traditional oral therapies .
Scope Of The Report
Report Attributes
Report Details
Report Title
Injectable Suspension Budesonide Market Research Report
By Type
0.5mg, 1mg
By Application
Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Other
By Companies
AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, AstraZeneca, Shanghai Sine Promod
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
216
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Injectable Suspension Budesonide Market Report Segments:
The global Injectable Suspension Budesonide market is segmented on the basis of:
Types
0.5mg, 1mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Teva
- Mylan
- Sandoz
- Cosmo Pharmaceuticals
- Salix
- Chiesi Farmaceutici
- Orion Corporation
- Cipla
- Synmosa Biopharma
- AstraZeneca
- Shanghai Sine Promod
Highlights of The Injectable Suspension Budesonide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.5mg
- 1mg
- By Application:
- Respiratory Disease Treatment
- Nose Disease Treatment
- Inflammatory Bowel Disease Treatment
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Injectable Suspension Budesonide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Injectable suspension budesonide is a medication used to treat asthma. It works by reducing the amount of air that your lungs can breathe. This helps to improve your breathing and reduce the symptoms of asthma.
Some of the key players operating in the injectable suspension budesonide market are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, AstraZeneca, Shanghai Sine Promod.
The injectable suspension budesonide market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Injectable Suspension Budesonide Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Injectable Suspension Budesonide Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Injectable Suspension Budesonide Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Injectable Suspension Budesonide Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Injectable Suspension Budesonide Market Size & Forecast, 2018-2028
4.5.1 Injectable Suspension Budesonide Market Size and Y-o-Y Growth
4.5.2 Injectable Suspension Budesonide Market Absolute $ Opportunity
Chapter 5 Global Injectable Suspension Budesonide Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Injectable Suspension Budesonide Market Size Forecast by Type
5.2.1 0.5mg
5.2.2 1mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Injectable Suspension Budesonide Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Injectable Suspension Budesonide Market Size Forecast by Applications
6.2.1 Respiratory Disease Treatment
6.2.2 Nose Disease Treatment
6.2.3 Inflammatory Bowel Disease Treatment
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Injectable Suspension Budesonide Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Injectable Suspension Budesonide Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Injectable Suspension Budesonide Analysis and Forecast
9.1 Introduction
9.2 North America Injectable Suspension Budesonide Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Injectable Suspension Budesonide Market Size Forecast by Type
9.6.1 0.5mg
9.6.2 1mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Injectable Suspension Budesonide Market Size Forecast by Applications
9.10.1 Respiratory Disease Treatment
9.10.2 Nose Disease Treatment
9.10.3 Inflammatory Bowel Disease Treatment
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Injectable Suspension Budesonide Analysis and Forecast
10.1 Introduction
10.2 Europe Injectable Suspension Budesonide Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Injectable Suspension Budesonide Market Size Forecast by Type
10.6.1 0.5mg
10.6.2 1mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Injectable Suspension Budesonide Market Size Forecast by Applications
10.10.1 Respiratory Disease Treatment
10.10.2 Nose Disease Treatment
10.10.3 Inflammatory Bowel Disease Treatment
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Injectable Suspension Budesonide Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Injectable Suspension Budesonide Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Injectable Suspension Budesonide Market Size Forecast by Type
11.6.1 0.5mg
11.6.2 1mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Injectable Suspension Budesonide Market Size Forecast by Applications
11.10.1 Respiratory Disease Treatment
11.10.2 Nose Disease Treatment
11.10.3 Inflammatory Bowel Disease Treatment
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Injectable Suspension Budesonide Analysis and Forecast
12.1 Introduction
12.2 Latin America Injectable Suspension Budesonide Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Injectable Suspension Budesonide Market Size Forecast by Type
12.6.1 0.5mg
12.6.2 1mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Injectable Suspension Budesonide Market Size Forecast by Applications
12.10.1 Respiratory Disease Treatment
12.10.2 Nose Disease Treatment
12.10.3 Inflammatory Bowel Disease Treatment
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Injectable Suspension Budesonide Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Injectable Suspension Budesonide Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Injectable Suspension Budesonide Market Size Forecast by Type
13.6.1 0.5mg
13.6.2 1mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Injectable Suspension Budesonide Market Size Forecast by Applications
13.10.1 Respiratory Disease Treatment
13.10.2 Nose Disease Treatment
13.10.3 Inflammatory Bowel Disease Treatment
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Injectable Suspension Budesonide Market: Competitive Dashboard
14.2 Global Injectable Suspension Budesonide Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Teva
14.3.3 Mylan
14.3.4 Sandoz
14.3.5 Cosmo Pharmaceuticals
14.3.6 Salix
14.3.7 Chiesi Farmaceutici
14.3.8 Orion Corporation
14.3.9 Cipla
14.3.10 Synmosa Biopharma
14.3.11 AstraZeneca
14.3.12 Shanghai Sine Promod
